Study shows recurrent alterations in prostate cancer in Chinese patients differ from those in the west

cancer
Killer T cells surround a cancer cell. Credit: NIH

A very large team of researchers affiliated with institutions across China (and several from Washington University School of Medicine in the U.S.) has found recurrent alterations in prostate cancer in Chinese patients that differ from patients in the west. In their paper published in the journal Nature, the group describes conducting transcriptomic, epigenomic and genomic analyses of prostate cancer tissue in patients in China and compared what they found with data from cancer patients in the west—and what they discovered as a result.

As the researchers note, much research has been conducted to better understand the nature of prostate —it is the second-most common type of cancer in men worldwide after . But they also note that most such research has been done with in the West. Curious as to whether there might be any differences between cancers in western men and those of men in China, they embarked on an ambitious study of prostate cancer in Chinese patients.

The work involved collecting tumor tissue samples from 208 patients who had been treated for prostate cancer with radical prostatectomy. For various reasons, some of the samples could not be used for their research—they wound up using just 177. By analyzing the tissue, the researchers found FOXA1 gene mutations in 41 percent of the tumors they studied. They also found recurrent CHD1 and ZNF292 deletions in approximately 18 percent of the tumors. They then discovered that both percentages were different compared to 2,554 prostate cancers found in patients in other parts of the world, which included 12 western countries. Prior research had also shown that approximately 50 percent of prostate tumors in the West have ETS fusions—a higher percentage than the team saw in Chinese patients.

The researchers suggest there are clear differences in in Chinese verses western patients—and that suggests more work is required to determine why. They also note that the data they collected in their study has been formatted and compiled into what they call the Chinese Prostate Cancer Genome and Epigenome Atlas.


Explore further

More time between prostate cancer screenings could improve outcomes

More information: Jing Li et al. A genomic and epigenomic atlas of prostate cancer in Asian populations, Nature (2020). DOI: 10.1038/s41586-020-2135-x
Journal information: Nature

© 2020 Science X Network

Citation: Study shows recurrent alterations in prostate cancer in Chinese patients differ from those in the west (2020, March 27) retrieved 1 June 2020 from https://medicalxpress.com/news/2020-03-recurrent-prostate-cancer-chinese-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
130 shares

Feedback to editors

User comments